352 related articles for article (PubMed ID: 26483398)
1. The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation.
Isernhagen A; Malzahn D; Viktorova E; Elsner L; Monecke S; von Bonin F; Kilisch M; Wermuth JM; Walther N; Balavarca Y; Stahl-Hennig C; Engelke M; Walter L; Bickeböller H; Kube D; Wulf G; Dressel R
EMBO Mol Med; 2015 Nov; 7(11):1480-502. PubMed ID: 26483398
[TBL] [Abstract][Full Text] [Related]
2. The MICA-129Met/Val dimorphism affects plasma membrane expression and shedding of the NKG2D ligand MICA.
Isernhagen A; Schilling D; Monecke S; Shah P; Elsner L; Walter L; Multhoff G; Dressel R
Immunogenetics; 2016 Feb; 68(2):109-23. PubMed ID: 26585323
[TBL] [Abstract][Full Text] [Related]
3. Impact of the MICA-129Met/Val Dimorphism on NKG2D-Mediated Biological Functions and Disease Risks.
Isernhagen A; Malzahn D; Bickeböller H; Dressel R
Front Immunol; 2016; 7():588. PubMed ID: 28018354
[TBL] [Abstract][Full Text] [Related]
4. MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.
Zingoni A; Vulpis E; Cecere F; Amendola MG; Fuerst D; Saribekyan T; Achour A; Sandalova T; Nardone I; Peri A; Soriani A; Fionda C; Mariggiò E; Petrucci MT; Ricciardi MR; Mytilineos J; Cippitelli M; Cerboni C; Santoni A
Front Immunol; 2018; 9():926. PubMed ID: 29765374
[TBL] [Abstract][Full Text] [Related]
5. Impact of donor NKG2D and MICA gene polymorphism on clinical outcomes of adult and paediatric allogeneic cord blood transplantation for malignant diseases.
Cox ST; Patterson W; Duggleby R; Jones OJR; Madrigal JA; Querol S; Salvador FR; Mata MJH; Volt F; Gluckman É; Szydlo R; Danby RD; Hernandez D
Eur J Haematol; 2024 Jul; 113(1):32-43. PubMed ID: 38511389
[TBL] [Abstract][Full Text] [Related]
6. Soluble MICA-NKG2D interaction upregulates IFN-γ production by activated CD3-CD56+ NK cells: potential impact on chronic graft versus host disease.
Boukouaci W; Al-Daccak R; Dulphy N; Lauden L; Amokrane K; Fortier C; Marzais F; Bennabi M; Peffault de Latour R; Socie G; Toubert A; Charron D; Krishnamoorthy R; Tamouza R
Hum Immunol; 2013 Dec; 74(12):1536-41. PubMed ID: 23994587
[TBL] [Abstract][Full Text] [Related]
7. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
Front Immunol; 2018; 9():1282. PubMed ID: 29963042
[TBL] [Abstract][Full Text] [Related]
8. A Valine Mismatch at Position 129 of
Michita RT; Chies JAB; Schramm S; Horn PA; Heinemann FM; Wunsch A; Viebahn R; Schenker P; Rebmann V
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30181474
[TBL] [Abstract][Full Text] [Related]
9. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
10. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
[TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
12. Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation.
Machuldova A; Holubova M; Caputo VS; Cedikova M; Jindra P; Houdova L; Pitule P
Front Immunol; 2021; 12():651751. PubMed ID: 33868289
[TBL] [Abstract][Full Text] [Related]
13. MICA and NKG2D variants as risk factors in spondyloarthritis: a case-control study.
Fechtenbaum M; Desoutter J; Delvallez G; Brochot E; Guillaume N; Goëb V
Genes Immun; 2019 Sep; 20(7):599-605. PubMed ID: 30177859
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
Sheng L; Mu Q; Wu X; Yang S; Zhu H; Wang J; Lai Y; Wu H; Sun Y; Hu Y; Fu H; Wang Y; Xu K; Sun Y; Zhang Y; Zhang P; Zhou M; Lai B; Xu Z; Gao M; Zhang Y; Ouyang G
Front Immunol; 2020; 11():1534. PubMed ID: 32849519
[No Abstract] [Full Text] [Related]
15. HLA-E polymorphism and clinical outcome after allogeneic hematopoietic stem cell transplantation in Egyptian patients.
Mossallam GI; Fattah RA; El-Haddad A; Mahmoud HK
Hum Immunol; 2015 Mar; 76(2-3):161-5. PubMed ID: 25543014
[TBL] [Abstract][Full Text] [Related]
16. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.
Kloss M; Decker P; Baltz KM; Baessler T; Jung G; Rammensee HG; Steinle A; Krusch M; Salih HR
J Immunol; 2008 Nov; 181(10):6711-9. PubMed ID: 18981088
[TBL] [Abstract][Full Text] [Related]
17. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions.
Allez M; Tieng V; Nakazawa A; Treton X; Pacault V; Dulphy N; Caillat-Zucman S; Paul P; Gornet JM; Douay C; Ravet S; Tamouza R; Charron D; Lémann M; Mayer L; Toubert A
Gastroenterology; 2007 Jun; 132(7):2346-58. PubMed ID: 17570210
[TBL] [Abstract][Full Text] [Related]
18. The Donor Major Histocompatibility Complex Class I Chain-Related Molecule A Allele rs2596538 G Predicts Cytomegalovirus Viremia in Kidney Transplant Recipients.
Rohn H; Tomoya Michita R; Schwich E; Dolff S; Gäckler A; Trilling M; Le-Trilling VTK; Wilde B; Korth J; Heinemann FM; Horn PA; Kribben A; Witzke O; Rebmann V
Front Immunol; 2018; 9():917. PubMed ID: 29867932
[TBL] [Abstract][Full Text] [Related]
19. Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.
Carapito R; Jung N; Kwemou M; Untrau M; Michel S; Pichot A; Giacometti G; Macquin C; Ilias W; Morlon A; Kotova I; Apostolova P; Schmitt-Graeff A; Cesbron A; Gagne K; Oudshoorn M; van der Holt B; Labalette M; Spierings E; Picard C; Loiseau P; Tamouza R; Toubert A; Parissiadis A; Dubois V; Lafarge X; Maumy-Bertrand M; Bertrand F; Vago L; Ciceri F; Paillard C; Querol S; Sierra J; Fleischhauer K; Nagler A; Labopin M; Inoko H; von dem Borne PA; Kuball J; Ota M; Katsuyama Y; Michallet M; Lioure B; Peffault de Latour R; Blaise D; Cornelissen JJ; Yakoub-Agha I; Claas F; Moreau P; Milpied N; Charron D; Mohty M; Zeiser R; Socié G; Bahram S
Blood; 2016 Oct; 128(15):1979-1986. PubMed ID: 27549307
[TBL] [Abstract][Full Text] [Related]
20. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
